Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Private equity giant Blackstone Life Sciences is paying Pfizer up to $1.5 billion to help fund development of berobenatide, a monthly GLP-1 receptor agonist. The deal signals a major shift in how Big Pharma is financing drug development — turning to private investors rather than traditional capital markets. Blackstone is essentially becoming a biotech bank, spreading drug-development risk across multiple pharma giants.
Private equity is rewriting the pharma financing playbook. Blackstone Life Sciences has struck a deal worth up to $1.5 billion with Pfizer to co-finance the development of berobenatide, a once-monthly GLP-1 receptor agonist that Pfizer acquired through its $9.8 billion takeover of Metsera last year. The drug is Pfizer's bid to compete in the weight management market dominated by Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
This isn't a one-off. Blackstone has quietly built a portfolio of similar financing arrangements with Apogee, Alnylam, Boston Scientific, J&J, Merck, and Moderna — effectively acting as a biotech bank. It's a notable reversal of the traditional model, where private capital backs early-stage startups and Big Pharma steps in for costly late-stage trials.
By the Numbers
Why it matters: As drug development costs soar, Big Pharma is increasingly offloading financial risk to private investors. This emerging model could reshape how blockbuster drugs get funded — and who profits when they succeed.
